Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
Date:1/27/2011

INDIANAPOLIS, Jan. 27, 2011 /PRNewswire/ --

  • Higher volume drove four percent revenue growth in Q4.
  • Gross margin improvements in Q4 led to growth in operating income.
  • Fourth quarter earnings per share grew to $1.05 (reported), or $1.11 (non-GAAP).
  • Full-year 2010 revenue topped $23 billion as eight human pharmaceutical medicines and the company's animal health business all exceed $1 billion in annual sales.
  • Full-year 2010 earnings per share grew to $4.58 (reported), or $4.74 (non-GAAP).
  • 2011 earnings per share guidance range set at $3.92 - $4.07 (reported), or $4.15 - $4.30 (non-GAAP).

  • Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2010.$ in millions, except per share data

    Fourth Quarter

    %

    Full Year

    %20102009

    Growth

    2010

    2009

    GrowthTotal Revenue – Reported

    $6,187.0$5,934.2

    4%

    $23,076.0

    $21,836.0

    6%Net Income – Reported

    1,169.6915.4

    28%

    5,069.5

    4,328.8

    17%EPS – Reported1.050.83

    27%

    4.58

    3.94

    16%Net Income – non-GAAP

    1,234.9999.4

    24%

    5,240.8

    4,851.0

    8%EPS – non-GAAP

    1.110.91

    22%

    4.74

    4.42

    7%Financial results for 2010 and 2009 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the period. Non-GAAP results exclude the items described in the reconciliation tables. The non-GAAP results are presented in order to provide additional insights into the underlying trends in the company's business. The company's 2011 financial guidanc
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
    3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
    4. Lilly Receives NCQA Design Certification for Depression Care Management Program
    5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
    6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
    7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
    8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
    9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
    10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
    11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
    (Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
    (Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
    Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
    ... Omnicell, Inc. (Nasdaq: OMCL ) a leading ... they will present at the UBS 21st Annual Global Healthcare ... Omnicell Speakers: Rob Seim, vice president ... DevelopmentDate: Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: ...
    ... LLC , ( www.curemark.com ), a drug research and ... recently hosted New York Senator Kirsten Gillibrand as she ... creation, locally and nationally.  Speaking at Curemark, which is ... proposal to expand, simplify and make permanent the Research ...
    Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Curemark Hosts New York Senator Kirsten Gillibrand 2Curemark Hosts New York Senator Kirsten Gillibrand 3
    (Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
    (Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
    (Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
    (Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
    (Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
    Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
    ... 19 The National Retail,Federation welcomed last night,s ... a House subcommittee to adopt the Senate,s version,when ... today. "The Senate bill is a strong ... while balancing the interests of employers," said NRF ...
    ... to treatments for diseases such as diabetes and Alzheimer,s , ... successfully reprogrammed adult stem cells from the testes of male ... blood vessels, contractile cardiac tissue, and brain cells. , If ... from humans, they may offer a source of new therapies ...
    ... plentiful this year, but inoculation rates are low, officials ... many Americans aren,t getting vaccinated for the flu, including ... workers -- U.S. health officials warned Wednesday. , "Despite ... still failing to protect a large proportion of people," ...
    ... accessed and plentiful, adult stem cells found in a male ... range of tissue types to help him fight disease -- ... , That,s the promise of a breakthrough study in mice ... New York City, who report their findings in the September ...
    ... International,( http://www.activator.com ), pioneer in chiropractic instrument,manufacturing and ... alliance,with three leading chiropractic companies to create the ... doctors improve the level of,care they provide patients, ... "What,s new about the Activator Advantage seminars is ...
    ... WASHINGTON, Sept. 19 More Americans will,have access ... bipartisan legislation passed by the U.S. Senate. The,"Mental ... plans that offer,mental health benefits to provide parity ... limitations. (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ) ...
    Cached Medicine News:Health News:Retailers Welcome Senate Passage of Mental Health Parity Bill, Urge House to Adopt Senate Version at Subcommittee Markup 2Health News:Stem Cells From Testes Produce Wide Range of Tissue Types 2Health News:More Americans Urged to Get Flu Shots 2Health News:More Americans Urged to Get Flu Shots 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 4Health News:New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nation's Chiropractic Care: Focus on the Patients 2
    ... The Burdick EK-10 single-channel,electrocardiograph ... touch membrane keypad. It ... make a quick and,accurate ... ergonomically,designed with a built ...
    The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
    ... CSV-1000LanC 10% test face is ... uses the Landolt C in ... targets. The targets are presented ... is very useful for evaluating ...
    ... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
    Medicine Products: